Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors-Results from an Exploratory Study.

Burcin ÖzdirikAnna K StuevenRaphael MohrLukas GeislerAlexander WreeJana KnorrMünevver DemirMihael VucurSven H LoosenFabian BenzMarkus ReissBertram WiedenmannFrank TackeHenning JannTeresa HellbergChristoph Roderburg

Published in: Journal of clinical medicine (2020)

Our data suggest a role for miR-29b serum levels as a previously unrecognized biomarker for diagnosis of NET. However, miR-29 does not allow for predicting tumor stage or patients' outcome.

Keyphrases

cell proliferation
neuroendocrine tumors
long non coding rna
end stage renal disease
long noncoding rna
chronic kidney disease
newly diagnosed
peritoneal dialysis
electronic health record
machine learning
patient reported outcomes
artificial intelligence
patient reported
deep learning